Research.uhb.nhs.uk

No. Research
Name of Trial
Date Agreed Trial Status
number of to recruit
Committee
patients
Reference
to recruit
number of
patients
agreed
time
A Randomized, Double-blind, Multiple Dose Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to An open, non-randomised, study to provide data on the arterial pressure wave form obtained through the Proxima 3 in patients who require the insertion of an arterial multicenter double-blind and open label 2 year extension study of subcutaneous secukinumab in prefilled syringes assessing long-term safety tolerability and efficacy A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients with type 2 diabetes fasting during Ramadan Randomized Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 & ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus Infection A Study to Evaluate the Efficacy and Safety of GFT505 80mg and GFT505 120mg once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH) A Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With double-blind randomized multicenter placebocontrolled parallel-group study to evaluate the efficacy and safety of fingolimod 0.5 mg administered orally once daily MEK114375: A rollover study to provide continued treatment with GSK1120212 to 10 13/NW/0028 subjects with solid tumors or leukemia A Randomised Phase 3 Study Comparing Cabazitaxel/Prednisone in combination with Curstirsen (OGX-011) to Cabazitaxel/Prednisone for Second-line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ? Ribavirin for 12 and 24 Weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV Infection Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 & ABT-333 Co-administered with Ribavirin in A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Cdeb025a2312: a Multi-centre 3-year Follow-up Study To Assess the Durability of Sustained Virologic Response in Alisporivir-treated Chronic Hepatitis C Patients An Open-Label Study of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection who Participated in Prior Studies Evaluating GS-7977 A Phase IIB/III Randomised, Double-blind, Placebo-controlled Study Comparing First-line Therapy with or without TG4010 Immunotherapy Product in Patients with Stage A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid- A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis A Multicenter, Randomized, Placebo-controlled Study of Sbc-102 in Patients With A multicentre, single arm study of Trastuzumab Emtasine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti- 6month Randomised Double-blind Placebo-controlled Multi-centre Parallel-group Phase2 Study with an Optional Safety Extension Treatment Period up to 6 month to Evaluate the Efficacy Safety and Tolerability of 3 Different Doses Open-label, single-arm, phase IV, multicentre trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with growth hormone deficiency (GHD) A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib A randomized, multi-center, open-label phase III study to evaluate the efficacy and safety of Trastuzumab Emtansine versus Trastuzumab as adjuvant therapy for patients with Her2-Positive Primary Breast Cancer who have residual Tumour Phase III, Randomized, Multicentre, Doubleblind, Doubledummy, Parallelgroup Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Versus Meropenem in the Treatment of Nosocomial 30 13/WA/0101 Pneumonia (NP) Including Ven A randomized, controlled study of sarilumab and methotrexate (MTX) versus etanercept and MTX in patients with rheumatoid arthritis (RA) and an inadequate response to 4 months of treatment with adalimumab and MTX A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple GS-US-292-0104. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 GS-US-292-0111: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of lvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Non-randomised, open label, single-arm prospective clinical investigation to assess the safety and performance of the Organox Metra for normothermic perfusion of livers prior to transplantation and compare with retrospective data from matched A phase Ib, open-label, multi-center, two-arm, dose-finding study to assess the safety and efficacy of the oral combination of Ruxolitinib (INC424) and BKM120 in patients with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis A phase 1/2, dose and schedule finding study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral Azacitidine (cc486) in subjects with acute Myeloid Leukemia or Myelodysplastic syndromes after Allogeneic A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma A MultiCenter, Randomized, Controlled, TwoArm, Pivotal Phase III Study to Evaluate the Safety and Efficacy of MK3475 Compared to Ipilimumab in Patients with An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, 41 10/H1107/59 or CD30-positive cutaneous T-cell lymphoma A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Combination with Ursodeoxycholic Acid (UDCA) in Patients with Primary Biliary A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate A Phase 3, Randomized, Doubleblind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe A 48 week, double-blind, randomized, multi-center, parallel-group study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute demyelinating A Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Obeticholic Acid (INT- 49 10/H0709/79 747) for the Treatment of Portal Hypertension (PESTO) A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma The efficacy and safety of Liraglutide as adjunct therapy to insulin in the treatment of Type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects A Multicenter, Randomized, DoubleBlind, PlaceboControlled, ParallelGroup Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC) A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm efficacy up to 80 weeks in subjects with moderate to MIRACLE EF - A prospective, randomized, controlled, double-blinded, global multi- center, Cardiac Resynchronization Therapy (CRT) in Heart Failure (HF) clinical study A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig in patients with Multifocal Motor Neuropathy A Randomized, Open-label, Multicenter, Controlled Study To Assess Safety and Efficacy of Elad® in Subjects With Alcohol-induced Liver Decompensation (AILD) A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Accu-Chek® Insight Insulin Pump EU Study: A European Multicenter Study to evaluate the safety and the day-to-day use of the Accu-Chek® Insight Insulin Pump

Source: http://www.research.uhb.nhs.uk/wp-content/uploads/2014/01/Performance-in-Delivery-for-PDF-Q3.pdf